Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOUSSAM AL KHARRAT

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1295734424
CMS profile
330526
Location
LUBBOCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,983.45

152 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,965.36 151
Education $18.09 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOUSSAM AL KHARRAT

NPI 1295734424 · CMS profile ID 330526

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

LUBBOCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295734424?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOUSSAM AL KHARRAT, NPI 1295734424, CMS profile ID 330526. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295734424?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HOUSSAM AL KHARRAT, NPI 1295734424, CMS profile ID 330526. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295734424?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HOUSSAM AL KHARRAT, NPI 1295734424, CMS profile ID 330526, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1295734424?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

152 matching records · $2,983.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 152 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 152.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AIMMUNE THERAPEUTICS, INC. $17.4609/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146996128 CMS
ABBVIE INC. $14.5308/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193214 CMS
AIMMUNE THERAPEUTICS, INC. $8.7208/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146997030 CMS
ABBVIE INC. $15.9608/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193212 CMS
Mallinckrodt Hospital Products Inc. $27.6008/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145045415 CMS
ABBVIE INC. $21.5408/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193210 CMS
Lilly USA, LLC $110.8708/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135022266 CMS
GENZYME CORPORATION $17.1208/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139609412 CMS
AIMMUNE THERAPEUTICS, INC. $14.8608/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146988611 CMS
ABBVIE INC. $24.3508/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193208 CMS
Daiichi Sankyo Inc. $26.0708/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089391950 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.8908/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137465653 CMS
PFIZER INC. $15.5108/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131888416 CMS
QOL Medical, LLC $21.7308/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147717087 CMS
ABBVIE INC. $2.9408/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193206 CMS
AIMMUNE THERAPEUTICS, INC. $0.6408/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146995620 CMS
AIMMUNE THERAPEUTICS, INC. $22.1208/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146995628 CMS
ABBVIE INC. $17.9007/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193204 CMS
Lilly USA, LLC $11.1007/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135029090 CMS
Daiichi Sankyo Inc. $14.5807/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089391948 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.5007/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137465647 CMS
Phathom Pharmaceuticals, Inc. $17.3407/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151033244 CMS
ABBVIE INC. $24.0407/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193202 CMS
ABBVIE INC. $11.1307/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193200 CMS
ABBVIE INC. $26.4407/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193198 CMS
AIMMUNE THERAPEUTICS, INC. $16.3807/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146979846 CMS
Regeneron Healthcare Solutions, Inc. $16.3707/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113996292 CMS
AIMMUNE THERAPEUTICS, INC. $12.3107/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146981386 CMS
Celgene Corporation $14.3907/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101195845 CMS
Takeda Pharmaceuticals U.S.A., Inc. $9.3907/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137465644 CMS
ABBVIE INC. $21.7107/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193196 CMS
PFIZER INC. $19.7806/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131652697 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.6506/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137465639 CMS
AIMMUNE THERAPEUTICS, INC. $15.7406/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146979876 CMS
Ipsen Biopharmaceuticals, Inc $19.8606/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091971076 CMS
Daiichi Sankyo Inc. $13.2706/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089391944 CMS
QOL Medical, LLC $37.7106/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147717085 CMS
Phathom Pharmaceuticals, Inc. $17.3106/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151033242 CMS
ABBVIE INC. $14.9406/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193194 CMS
AIMMUNE THERAPEUTICS, INC. $13.4306/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146980348 CMS
AIMMUNE THERAPEUTICS, INC. $1.5906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146980244 CMS
Daiichi Sankyo Inc. $25.6606/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089391946 CMS
Merck Sharp & Dohme LLC $21.9506/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141628209 CMS
ABBVIE INC. $19.3406/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193192 CMS
ABBVIE INC. $19.4506/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193190 CMS
PFIZER INC. $28.4905/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131524435 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.9405/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137465635 CMS
ABBVIE INC. $20.9305/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103193188 CMS
Ardelyx, Inc. $14.7605/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146667664 CMS
AIMMUNE THERAPEUTICS, INC. $20.1105/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146979980 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,203.97 83
PY2020 $1,622.97 87
PY2021 $2,161.69 118
PY2022 $2,247.06 134
PY2023 $2,541.75 140
PY2024 $2,983.45 152
PY2025 $2,958.11 147

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $304,539.18 32
PY2024 Principal investigator $148,327.53 35
PY2023 Principal investigator $122,297.11 26
PY2022 Principal investigator $214,476.77 113
PY2021 Recipient $50.04 1
PY2021 Principal investigator $412,497.92 113
PY2020 Recipient $10,204.00 1
PY2020 Principal investigator $53,710.73 56
PY2019 Principal investigator $7,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $7,826.82 12/04/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202527214
Principal investigator 1 ABBVIE INC. $123,900.00 11/20/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202524842
Principal investigator 1 ABBVIE INC. $4,860.80 11/05/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202522081
Principal investigator 1 ABBVIE INC. $1,331.20 11/04/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202520459
Principal investigator 1 Janssen Research & Development, LLC $157.00 10/29/2025 Non-covered Recipient Entity
Caprock Gastro Rsrch Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175283032
Principal investigator 1 Janssen Research & Development, LLC $157.00 10/29/2025 Non-covered Recipient Entity
Caprock Gastro Rsrch Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175283048
Principal investigator 1 Janssen Research & Development, LLC $157.00 10/29/2025 Non-covered Recipient Entity
Caprock Gastro Rsrch Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175283073
Principal investigator 1 ABBVIE INC. $21,944.16 10/09/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202514209
Principal investigator 1 ABBVIE INC. $17,850.00 09/04/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202509488
Principal investigator 1 ABBVIE INC. $2,171.00 09/03/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202507911
Principal investigator 1 Janssen Research & Development, LLC $1,032.00 08/21/2025 Non-covered Recipient Entity
Caprock Gastro Rsrch Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175283065
Principal investigator 1 Janssen Research & Development, LLC $1,471.00 08/21/2025 Non-covered Recipient Entity
Caprock Gastro Rsrch Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175283095
Principal investigator 1 Janssen Research & Development, LLC $1,032.00 08/21/2025 Non-covered Recipient Entity
Caprock Gastro Rsrch Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175283108
Principal investigator 1 Janssen Research & Development, LLC $157.00 08/21/2025 Non-covered Recipient Entity
Caprock Gastro Rsrch Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175283125
Principal investigator 1 ABBVIE INC. $9,482.48 08/06/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202503041
Principal investigator 1 ABBVIE INC. $26,767.72 07/08/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202497218
Principal investigator 1 ABBVIE INC. $27,459.60 07/02/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202495233
Principal investigator 1 Janssen Research & Development, LLC $1,471.00 06/23/2025 Non-covered Recipient Entity
Caprock Gastro Rsrch Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175283025
Principal investigator 1 Janssen Research & Development, LLC $157.00 06/23/2025 Non-covered Recipient Entity
Caprock Gastro Rsrch Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175283055
Principal investigator 1 Janssen Research & Development, LLC $157.00 06/23/2025 Non-covered Recipient Entity
Caprock Gastro Rsrch Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175283084
Principal investigator 1 Eli Lilly and Company $1,014.78 06/13/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187875441
Principal investigator 1 Eli Lilly and Company $942.88 06/13/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187878349
Principal investigator 1 ABBVIE INC. $8,215.50 06/03/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202489709
Principal investigator 1 ABBVIE INC. $19,617.15 05/07/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202483615
Principal investigator 1 ABBVIE INC. $8,215.50 05/06/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202481987
Principal investigator 1 Eli Lilly and Company $168.48 04/23/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187877967
Principal investigator 1 Eli Lilly and Company $9,970.00 04/15/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187876481
Principal investigator 1 ABBVIE INC. $1,106.91 04/03/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202473631
Principal investigator 1 ABBVIE INC. $1,085.50 03/06/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202458091
Principal investigator 1 ABBVIE INC. $1,085.50 02/05/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202444995
Principal investigator 1 Janssen Research & Development, LLC $2,244.00 01/27/2025 Non-covered Recipient Entity
Caprock Gastro Rsrch Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175283101
Principal investigator 1 ABBVIE INC. $1,331.20 01/02/2025 Non-covered Recipient Entity
CAPROCK GASTRO RESEARCH LLC
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202434770